ArticleCurrent issues in molecular biology2026
POU6F1 Expression Predicts Favorable Prognosis in Lung Adenocarcinoma: Validation Using Patient Cohort and TCGA Data.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subtype-Specific Prognostic and Molecular Significance of ADGRD1 in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a leading cause of cancer-related mortality worldwide. Lung adenocarcinoma (AD) and lung squamous cell carcinoma (SCC) represent the two major histological subtypes with distinct molecular characteristics. POU domain class 6 transcription factor 1 (POU6F1) is involved in gene regulation and cellular differentiation, but its clinical significance in NSCLC remains unclear. This study investigated the clinicopathologic and prognostic significance of POU6F1 expression in NSCLC. POU6F1 mRNA expression was analyzed in tumor tissues obtained from 153 patients with NSCLC using quantitative real-time polymerase chain reaction. The associations between POU6F1 expression and clinicopathological characteristics were evaluated, and survival analysis was performed to determine its prognostic value. In addition, publicly available datasets from The Cancer Genome Atlas (TCGA) were analyzed to validate the clinical significance of POU6F1 expression. High POU6F1 expression was observed in 48 patients (31.4%), whereas 105 patients (68.6%) showed low expression. High POU6F1 expression was significantly associated with younger age (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.